Search Results - Mehdi Hamadani

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

    Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study by Alison Sehgal, Daanish Hoda, Peter A. Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C. Hildebrandt, John E. Godwin, Patrick M. Reagan, Nina D. Wagner-Johnston, James Essell, Rajneesh Nath, Scott R. Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Victor A. Chow, Brenda Yuan, Zhi Yang, Ken Ogasawara, Jerill Thorpe, Leo I. Gordon

    Published 2025-08-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703

    Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703 by Sameem Abedin, Michael J. Martens, Javier Bolaños-Meade, Monzr M. Al Malki, Qinghua Lian, Lyndsey Runaas, Hany Elmariah, Mahasweta Gooptu, Karilyn T. Larkin, Brian C. Shaffer, Alison W. Loren, Melhem Solh, Amin M. Alousi, Omer H. Jamy, Miguel-Angel Perales, Andrew Rezvani, Ami Bhatt, Najla El Jurdi, Janny M. Yao, Kristy Applegate, Leslie S. Kean, Yvonne A. Efebera, Ran Reshef, William Clark, Eric Leifer, Wael Saber, Mary M. Horowitz, Richard J. Jones, Shernan G. Holtan, Mehdi Hamadani

    Published 2025-07-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: